NIH R01 · 2025
CD200R blockade for cancer immunotherapy
PROJECT SUMMARY Immunotherapies based on the blockade of immune checkpoints have revolutionized cancer treatment in recent years. Today, immune checkpoint inhibitors in development aim to reactivate tumor-infiltrating T cells to facilitate tumor cell death. In many tumor types, however, the most abundant form of infiltrating immune cells are myeloid cells, such as macrophages, neutrophils, and eosinophils, which can be tumoricidal as well as tumor promoting. Consequently, targeting immune checkpoints that regulate both T cells and myeloid cells may have broad implications for cancer immunotherapy. CD200R, initially identified as a myeloid-restricted, inhibitory immune receptor, was later…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.